PANCAID Consortium Selects biomodal’s duet 6-Base Mosaic Technology to Advance Early Pancreatic Cancer Detection

PANCAID Consortium Selects biomodal’s duet 6-base mosaic Technology to Support Early Detection of Pancreatic Cancer

biomodal, an omics-based life sciences technology and analytics company, has announced that PANCAID (PANcreatic CAncer Initial Detection via liquid biopsy), a pan-European research consortium comprising 18 partner institutions across eight countries, has adopted its duet 6-base mosaic sequencing technology for research into the early detection of pancreatic cancer.

The collaboration will focus on identifying and evaluating complementary molecular biomarkers in circulating cell-free DNA (cfDNA) collected from patients with pancreatic cancer and healthy individuals. By combining genetic, epigenetic and fragmentomic information from the same original DNA molecules, the research teams aim to investigate molecular patterns that could help identify pancreatic cancer at an earlier stage.

PANCAID is working to develop an advanced early-detection approach for pancreatic ductal adenocarcinoma (PDAC), one of the most aggressive and lethal forms of cancer. The consortium is integrating multiple biomarker types with artificial intelligence (AI)-based analytical approaches and plans to evaluate the strategy through a prospective, multicentre screening trial.

The adoption of biomodal’s duet 6-base mosaic technology represents an important component of this research strategy. The platform enables researchers to obtain multiple types of molecular information from a single cfDNA sample, potentially maximizing the analytical value of limited biological material. This capability is particularly important for PANCAID because the consortium is investigating several liquid biopsy analytes using plasma samples collected from patients and healthy controls across Europe.

Through the collaboration, biomodal will support researchers in examining genetic alterations, DNA methylation patterns and DNA fragmentation characteristics within the same sequencing workflow. The resulting data will be jointly analyzed by scientific teams at the Medical University of Graz in Austria and the Hebrew University of Jerusalem (HUJI), with research leadership and collaboration involving Ellen Heitzer, Yuval Dor and Tommy Kaplan.

Addressing the Challenge of Early Pancreatic Cancer Detection

Pancreatic cancer continues to represent a significant challenge in oncology because the disease frequently develops without producing noticeable symptoms during its early stages. Consequently, many patients are diagnosed only after the cancer has progressed, when treatment options may be limited and the likelihood of achieving favorable clinical outcomes is considerably reduced.

Pancreatic ductal adenocarcinoma is the most common form of pancreatic cancer and is particularly difficult to detect at an early stage. The absence of reliable early warning signs and the complexity of identifying disease-associated molecular changes have created a substantial need for more sensitive and minimally invasive diagnostic approaches.

Early detection could provide an opportunity to identify the disease before it reaches an advanced stage, potentially allowing patients to access treatment and clinical management strategies sooner.

Liquid biopsy technologies are receiving increasing attention as potential tools for addressing this challenge. Unlike conventional diagnostic approaches that may require tissue samples, liquid biopsy methods analyze biological material circulating in blood, including cell-free DNA released by cells into the bloodstream.

In cancer patients, cfDNA can contain molecular alterations associated with tumor development and progression. These alterations may include genetic mutations, epigenetic modifications and changes in DNA fragmentation patterns. Examining these molecular characteristics could help researchers identify disease-associated signals that may not be detectable through conventional approaches.

However, early-stage pancreatic cancer presents additional analytical difficulties. The amount of tumor-derived DNA circulating in the bloodstream may be extremely limited, making it challenging to distinguish cancer-associated molecular signals from background DNA originating from healthy cells.

PANCAID aims to address these limitations through a multi-analyte liquid biopsy strategy that combines several complementary biomarkers and advanced AI-based analysis. The consortium is investigating whether integrating different molecular signals can improve the identification of pancreatic cancer and its precursor lesions.

PANCAID Consortium Brings Together 18 Institutions Across Eight Countries

PANCAID is a European research initiative involving 18 partner institutions across eight countries. The consortium brings together expertise in cancer research, molecular diagnostics, liquid biopsy technologies, genomics, computational biology and clinical research.

Its primary objective is to develop an approach for detecting pancreatic ductal adenocarcinoma and precursor lesions at an early stage by integrating multiple biomarker types through AI-based analytical methods.

The research program includes a prospective, multicentre screening trial designed to evaluate the potential clinical application of the developed approach.

As part of its research activities, PANCAID partners have collected plasma samples over several years from individuals with pancreatic cancer and healthy controls. These samples provide an important resource for investigating molecular characteristics associated with pancreatic cancer and evaluating potential biomarkers for early detection.

The plasma samples collected by consortium partners across Europe have been centrally processed and extracted at the Medical University of Graz in Austria.

However, the research involves analyzing multiple liquid biopsy analytes from the same blood samples. As a result, only limited plasma volumes have been available for extracting cfDNA for individual research applications.

This creates an important technical challenge. Researchers need to obtain as much molecular information as possible from each available sample without unnecessarily dividing the limited cfDNA material among multiple separate analytical workflows.

The ability to investigate several complementary biomarkers from the same original DNA molecules is therefore central to the consortium’s research strategy.

duet 6-base mosaic Enables Integrated Genetic, Epigenetic and Fragmentomic Analysis

To address the limitations associated with scarce cfDNA samples, PANCAID has adopted biomodal’s duet 6-base mosaic sequencing technology.

The platform provides an integrated workflow that enables researchers to examine genetic, epigenetic and fragmentomic characteristics from a single cfDNA sample. By combining these molecular measurements within one analytical process, the technology supports a more comprehensive investigation of potential cancer-associated biomarkers.

The duet 6-base mosaic workflow uses biomodal’s proprietary single-stranded ligation chemistry to analyze multiple molecular features from the same original cfDNA molecules.

Its capabilities include the identification of genetic variants, the analysis of DNA methylation and the assessment of DNA fragmentation patterns.

One of the important features of the technology is its ability to distinguish between two DNA modifications: 5-methylcytosine (5mC) and 5-hydroxymethylcytosine (5hmC).

Both modifications are involved in epigenetic regulation and can provide information about biological processes that influence gene activity and cellular behavior. Although they are chemically related, 5mC and 5hmC represent distinct DNA modifications and may provide different biological insights.

Being able to distinguish these modifications within the same sequencing workflow could help researchers investigate a broader range of epigenetic changes associated with pancreatic cancer.

In addition to genetic and epigenetic analysis, duet 6-base mosaic retains fragmentomic information, including DNA fragment lengths and end motifs.

Fragmentomic analysis examines the physical characteristics of DNA fragments circulating in the bloodstream. Differences in fragment size distributions and DNA fragment end patterns may provide additional information about the biological processes responsible for DNA release and degradation.

These characteristics can also support investigations into nucleosome positioning, which may provide further insights into the tissue and cellular origins of circulating DNA.

By combining genetic variants, DNA methylation, hydroxymethylation and fragmentation characteristics, the platform allows researchers to investigate multiple molecular signals without requiring separate assays for each biomarker category.

For PANCAID, this integrated approach is particularly valuable because it allows the consortium to maximize the information obtained from limited cfDNA quantities while supporting its broader multi-analyte liquid biopsy strategy.

Collaborative Data Analysis Between European and Israeli Research Teams

Data generation using the duet 6-base mosaic technology is currently ongoing as part of the PANCAID research program.

Once generated, the sequencing data will be jointly analyzed by research teams at the Medical University of Graz and the Hebrew University of Jerusalem.

The work at the Medical University of Graz is led by Professor Ellen Heitzer, who heads the Institute of Human Genetics. The collaboration with the Hebrew University of Jerusalem involves researchers Yuval Dor and Tommy Kaplan.

The combined expertise of these research groups will support the evaluation of genetic, epigenetic and fragmentomic biomarkers in samples collected from pancreatic cancer patients and healthy controls.

The analysis will investigate how different molecular signals may complement one another and whether their integration can help identify patterns associated with early pancreatic cancer.

The availability of multiple molecular measurements from the same cfDNA molecules may also help researchers explore relationships between different biomarker categories.

For example, genetic alterations can provide information about mutations associated with cancer, while epigenetic modifications may reveal changes in DNA regulation. Fragmentation patterns can contribute additional information about the characteristics and potential origins of circulating DNA.

Combining these signals could provide a more comprehensive molecular profile than analyzing individual biomarker categories independently.

The consortium’s broader objective is to determine whether these complementary molecular features, when evaluated using AI-based approaches, can support the identification of pancreatic cancer and its precursor lesions at an earlier stage.

Researchers Highlight the Importance of Maximizing Limited cfDNA Samples

Professor Ellen Heitzer, Head of the Institute of Human Genetics at the Medical University of Graz, emphasized the importance of obtaining multiple types of molecular information from limited quantities of cfDNA.

She explained that early pancreatic cancer detection requires researchers to identify subtle molecular signals that may be present in very small amounts of circulating DNA.

For the PANCAID research program, the ability to investigate genetic alterations, distinguish 5mC from 5hmC and analyze DNA fragmentation patterns within the same sample is particularly valuable.

According to Professor Heitzer, the integrated approach enables researchers to make better use of carefully collected biobank samples while investigating complementary biomarkers that could contribute to earlier pancreatic cancer detection.

Her comments highlight one of the major advantages of integrating multiple molecular measurements into a single sequencing workflow.

Because PANCAID is evaluating several liquid biopsy analytes from the same plasma samples, preserving and efficiently utilizing the available cfDNA is essential for generating meaningful research results.

The ability to examine several molecular characteristics from the same original DNA molecules could reduce the need to allocate limited sample material across multiple separate assays.

This may allow the consortium to investigate a wider range of potential biomarkers while maintaining access to valuable samples for other analytical applications.

biomodal Emphasizes the Potential of Integrated Sequencing for Cancer Research

Robert Osborne, Senior Vice President of Research and Development at biomodal, highlighted the importance of the PANCAID collaboration and the challenges associated with detecting pancreatic cancer at an early stage.

He explained that early detection of pancreatic cancer represents a particularly demanding research challenge because the disease can produce subtle molecular signals and researchers often have access to only small quantities of cfDNA.

According to Osborne, duet 6-base mosaic was developed to address research requirements involving complex molecular signals and limited DNA samples while generating reliable and comprehensive sequencing data.

He also noted that PANCAID brings together leading liquid biopsy researchers from across Europe and provides an important research environment in which the technology can be evaluated through its application in the prospective screening trial.

Osborne stated that biomodal is proud to support the consortium’s efforts to develop a blood test capable of identifying pancreatic cancer early enough to potentially improve patient outcomes.

The collaboration also demonstrates the growing importance of integrated sequencing technologies in translational cancer research, particularly in areas where multiple molecular biomarkers may be needed to improve disease detection.

Integrated Software Pipeline Supports Large-Scale Research Analysis

In addition to its sequencing technology, biomodal provides a dedicated computational analysis solution to support the processing and interpretation of sequencing data.

Every duet mosaic kit includes biomodal’s duet software pipeline, which is designed to support the analysis of data generated through the company’s integrated sequencing workflow.

As part of the PANCAID collaboration, the consortium has installed the duet software pipeline on its own high-performance computing infrastructure.

This enables the research teams to process sequencing data at scale within their existing computational environment.

The availability of an integrated software pipeline is an important component of the overall workflow because the analysis of genetic, epigenetic and fragmentomic information requires appropriate computational tools to process and interpret the different molecular signals.

By combining the sequencing workflow with dedicated analytical software, biomodal aims to support researchers in generating and evaluating comprehensive molecular datasets.

For PANCAID, this infrastructure will help facilitate the analysis of hundreds of pancreatic cancer and matched healthy-control samples as data generation continues.

Advancing Multi-Omics Liquid Biopsy Research for Pancreatic Cancer

The adoption of biomodal’s duet 6-base mosaic technology by the PANCAID consortium represents an important development in the application of multi-omics sequencing to early cancer detection research.

By enabling the analysis of genetic, epigenetic and fragmentomic characteristics from a single cfDNA sample, the technology addresses a key challenge in liquid biopsy research: obtaining comprehensive molecular information from limited biological material.

The collaboration brings together biomodal’s integrated sequencing and analytical capabilities with the clinical and scientific expertise of 18 partner institutions across eight countries.

As data generation and collaborative analysis continue, researchers will investigate whether combining complementary molecular biomarkers with AI-based approaches can improve the early identification of pancreatic ductal adenocarcinoma and its precursor lesions.

Although the technology is currently being evaluated within the PANCAID research program, the findings generated through this work could contribute to the development of more comprehensive and minimally invasive approaches for pancreatic cancer screening.

Ultimately, the consortium aims to advance a blood-based detection strategy that could identify pancreatic cancer earlier, when patients may have more opportunities for effective clinical intervention. The collaboration also highlights the potential of integrated multi-omics technologies to support the next generation of precision diagnostics and cancer detection research.

About biomodal ltd.

biomodal is an omics-based life sciences technology and analytics company delivering products that bring the dynamism of our ever-changing biology into focus. Our duet solutions enable more epigenetic information from a single, low-input DNA sample without complex, resource intensive bioinformatics or harsh chemical treatment. Our single-base-resolution sequencing approach unlocks the combinatorial power of genetic and epigenetic information, elucidating greater biological insight within the fields of cancer, neurodegenerative disease, and ageing.

Source Link

Newsletter Updates

Enter your email address below and subscribe to our newsletter